Impact of Structural Biology in an Increasingly Fast-Paced Drug Discovery Environment
- Addressing the perceived mismatch between rapid AI-driven discovery cycles and slower experimental structural biology workflows
- Ensuring structural biology remains a critical decision-making tool rather than a downstream support function
- Integrating structural biology, computational chemistry, and AI/ML teams to drive confident discovery decisions
- Lessons from building cross-functional structural biology capabilities within a modern pharma organization